Orchestra BioMed Holdings Inc. (OBIO)
OBIO trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1814114/000110465926026754/0001104659-26-026754-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OBIO on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001814114 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $33.5M |
| Net income | -$52.7M |
| Operating income | -$51.8M |
| Net margin | -157.4% |
| Operating margin | -154.7% |
| Revenue growth | +1169.2% |
| Cash | $34.7M |
| Total assets | $114.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 16.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $27.8M cash; operating cash flow -$15.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 78,704,957 (2026-11-09); 56,464,731 a year earlier; 35,743,972 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-11-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $280K, sold $258K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $91K | -$18.8M | -$19.5M | $27.8M | No debt tags | $31.2M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $88K | -$23.8M | -$19.3M | $20.5M | No debt tags | $32.0M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $110K | -$20.7M | -$22.2M | $28.4M | $15.0M | $32.7M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $30.9M | $6.2M | -$2.3M | $34.7M | $15.0M | $33.5M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $861K | -$20.8M | -$14.6M | $42.0M | $15.0M | $2.8M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $836K | -$19.4M | -$15.5M | $18.7M | $15.0M | $2.9M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $868K | -$18.8M | -$16.6M | $18.3M | $15.0M | $2.9M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $253K | -$16.2M | -$13.5M | $22.3M | $15.0M | $2.6M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-06 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-06-16 |
Source: SEC EDGAR submissions feed, 422 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +27.6% |
| 1 month | +26.7% |
| 3 months | +62.9% |
| Year to date | +74.7% |
| 1 year | +73.4% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
| CRON | Cronos Group Inc. Common Share | $3.27 | -3.25% | $1.2B |
| USNA | USANA Health Sciences Inc. | $13.54 | +2.27% | $250.3M |
| CGC | Canopy Growth Corporation Common Shares | $0.5460 | -2.71% | $231.2M |
| MDWD | MediWound Ltd. | $13.55 | +5.04% | $195.0M |
| RLX | RLX Technology Inc. | $1.53 | -1.92% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier